Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PPIH
2276
Perma-Pipe International
PPIH
$218M
| $2.23M | ﹤0.01% |
237,442
+4,164
| +2% | +$38.2K |
|
|
ALYA
2277
DELISTED
Alithya Group Inc Class A Subordinate Voting Shares
ALYA
| $2.22M | ﹤0.01% |
798,411
-10,154
| -1% | -$27.1K |
|
|
EBTC
2278
DELISTED
Enterprise Bancorp
EBTC
| $2.22M | ﹤0.01% |
65,448
+10,896
| +20% | +$337K |
|
|
SLCT
2279
DELISTED
Select Bancorp, Inc.
SLCT
| $2.22M | ﹤0.01% |
180,261
+19,600
| +12% | +$230K |
|
|
HMSY
2280
DELISTED
HMS Holdings Corp.
HMSY
| $2.22M | ﹤0.01% |
74,912
+3,212
| +4% | +$98.6K |
|
|
FFWM
2281
DELISTED
First Foundation Inc
FFWM
| $2.21M | ﹤0.01% |
127,265
-8,500
| -6% | -$137K |
|
2282
GDS Holdings
GDS
$6.89B
| $2.2M | ﹤0.01% |
+42,700
| New | +$1.91M |
|
2283
iShares California Muni Bond ETF
CMF
$4.62B
| $2.2M | ﹤0.01% |
35,900
+10,800
| +43% | +$661K |
|
2284
O-I Glass
OI
$1.04B
| $2.19M | ﹤0.01% |
+184,000
| New | +$1.84M |
|
2285
Arcus Biosciences
RCUS
$3.75B
| $2.19M | ﹤0.01% |
217,238
+76,400
| +54% | +$642K |
|
|
NOTV
2286
DELISTED
Inotiv
NOTV
| $2.19M | ﹤0.01% |
441,704
+107,202
| +32% | +$472K |
|
2287
Sportsman's Warehouse
SPWH
$46.4M
| $2.18M | ﹤0.01% |
+271,100
| New | +$1.92M |
|
2288
Green Dot
GDOT
$771M
| $2.17M | ﹤0.01% |
92,900
-107,800
| -54% | -$2.69M |
|
2289
Upwork
UPWK
$1.06B
| $2.16M | ﹤0.01% |
202,817
+81,717
| +67% | +$1.03M |
|
2290
NetSol Technologies
NTWK
$48.3M
| $2.16M | ﹤0.01% |
540,444
+26,631
| +5% | +$123K |
|
2291
Norwood Financial Corp
NWFL
$376M
| $2.16M | ﹤0.01% |
55,427
+2,788
| +5% | +$95.1K |
|
2292
Ultralife
ULBI
$125M
| $2.15M | ﹤0.01% |
291,264
-17,008
| -6% | -$141K |
|
2293
Millicom
TIGO
$15.7B
| $2.15M | ﹤0.01% |
44,547
+28,947
| +186% | +$1.33M |
|
2294
Standard Motor Products
SMP
$870M
| $2.14M | ﹤0.01% |
40,200
-44,300
| -52% | -$2.26M |
|
|
EIGR
2295
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.13M | ﹤0.01% |
4,771
-1,940
| -29% | -$689K |
|
2296
iShares MSCI France ETF
EWQ
$332M
| $2.13M | ﹤0.01% |
+65,100
| New | +$2.04M |
|
|
MN
2297
DELISTED
MANNING & NAPIER, INC.
MN
| $2.12M | ﹤0.01% |
1,218,699
-500
| -0% | -$873 |
|
|
CMA
2298
DELISTED
Comerica
CMA
| $2.12M | ﹤0.01% |
+29,547
| New | +$2.03M |
|
|
NP
2299
DELISTED
Neenah, Inc. Common Stock
NP
| $2.12M | ﹤0.01% |
30,100
+25,300
| +527% | +$1.72M |
|
2300
STRATTEC Security
STRT
$348M
| $2.12M | ﹤0.01% |
95,324
+11,859
| +14% | +$259K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.